6-Methyl nicotine (often abbreviated 6-MN) is a synthetic analog of nicotine that has appeared in e-cigarettes and oral pouch products in the United States, marketed under brand names like “Metatine.” Based on the research published so far, it is not safe: animal studies show it is roughly two to five times more acutely toxic than nicotine, and lab studies on human lung cells find it causes more cell damage and generates more harmful reactive molecules than nicotine does. Despite this, it has been sold to consumers with little regulatory oversight, exploiting a gap in how U.S. tobacco law defines “nicotine.”
What 6-Methyl Nicotine Actually Is
At its core, 6-MN is nicotine with one small chemical addition: an extra methyl group attached to the pyridine ring at what chemists call the 6-position. That single change is enough to alter how the molecule behaves in the body, how it’s metabolized, and how toxic it is. The compound was patented by a Chinese e-cigarette manufacturer and entered the U.S. market under the trade name “Metatine,” primarily in a brand called Spree Bar.
6-MN does exist naturally in tobacco, but at vanishingly small concentrations. An analysis of various tobacco products found an average of about 0.32 micrograms of 6-MN per gram of tobacco material, thousands of times lower than the nicotine content in those same products.1Scientific Reports. Levels of the nicotine analog 6-methyl nicotine as a naturally formed tobacco alkaloid in tobacco and tobacco products The 6-MN found in commercial e-cigarette products isn’t harvested from tobacco leaves; it’s synthesized in a lab. Products like Spree Bar have been confirmed through mass spectrometry to contain a compound matching the molecular weight of 6-methyl nicotine.2PubMed Central. An electronic cigarette pod system delivering 6-methyl nicotine, a synthetic nicotine analog, marketed in the United States as “PMTA exempt”
Why a Single Methyl Group Matters So Much
You might wonder how adding one tiny chemical group to an already-dangerous molecule could make a meaningful difference. The answer lies in how the modified molecule interacts with receptors in the nervous system. In a study examining how nicotine analogs compete for binding at nicotinic receptors in the brain, a methyl group at the 6-position resulted in over three-fold greater potency compared to nicotine itself.3Drug Development Research. Structure–activity relationships for nicotine analogs comparing competition for [3H]nicotine binding and psychotropic potency That means at a given dose, 6-MN hits the brain’s nicotine receptors harder than nicotine does.
Greater potency at receptors doesn’t just mean a stronger buzz. It raises the floor for concern about addiction. If a substance activates the brain’s reward circuits more powerfully per milligram, preclinical researchers expect it to carry a higher dependence risk. Preclinical studies found 6-MN to be at least three times more potent than nicotine at triggering characteristic behavioral responses, with a lower lethal dose, raising concerns about both increased addictiveness and greater toxicity.4Tobacco Prevention & Cessation. Introduction of nicotine analogue-containing oral pouch products in the United States
An animal study in middle-aged female rats found that a given dose of 6-MN produced effects on body temperature, physical activity, and pain sensitivity that were comparable in magnitude to the same dose of nicotine, and the rats self-administered 6-MN vapor at a similar rate to nicotine vapor.5bioRxiv. Effects of 6-methyl nicotine in middle aged female rats with a history of nicotine vapor self-administration In other words, animals given access to 6-MN treat it much like they treat nicotine, using roughly the same amount and showing parallel physiological responses.
Acute Toxicity in Animal Studies
One of the most alarming findings about 6-MN involves how much more lethal it is in standard animal toxicity tests. Multiple studies have examined the lethal dose (the dose that kills half of exposed animals in a controlled test). One set of results, drawing on historical tobacco industry data from intravenous mouse assays, found that racemic 6-MN was roughly four times as acutely toxic as nicotine, while the S-enantiomer was about two-and-a-half times as toxic.6Toxicology Reports. Toxicological and pharmacodynamic evaluation of Nixodine-S [(S)-6-Methylnicotine] relative to (S)-nicotine Death was mediated through central nervous system toxicity, and the dose needed to cause convulsions was also dramatically lower for 6-MN than for nicotine.
A separate health risk assessment reported similar numbers from rodent studies: the dose of 6-MN needed to cause convulsions and the lethal dose were both about two to three times lower than the corresponding values for nicotine.7PubMed Central. Health Risk Assessment for an Unregulated Neurotoxic Nicotine Analogue in Oral Pouch Products The two studies used somewhat different methods and reported slightly different fold-differences, but the direction is consistent: 6-MN is substantially more dangerous per milligram than nicotine in acute exposure.
What It Does to Human Lung Cells
Animal lethality data tells you about poisoning risk, but a different question is what happens to the tissues that are exposed to 6-MN aerosol over time, especially the lungs. Several lab studies using human bronchial epithelial cells (the cells lining your airways) have looked at this directly.
When researchers heated 6-MN-containing e-liquids to generate aerosol, the aerosol contained significantly more reactive oxygen species (ROS) than aerosol from nicotine e-liquids. Those same 6-MN aerosols caused more cell death and triggered more oxidative stress inside the lung cells in a dose-dependent way. The study’s conclusion was blunt: 6-MN “cannot be deemed ‘safer’ than nicotine.”8Toxicology Letters. Emerging nicotine analog 6-methyl nicotine increases reactive oxygen species in aerosols and cytotoxicity in human bronchial epithelial cells
A separate study using a different line of human bronchial cells went further. It found that the cells were more sensitive to 6-MN than to nicotine and used gene-expression analysis to look at which biological pathways were being disrupted. The 6-MN-exposed cells showed over 1,200 differentially expressed cancer-related proteins, and these were significantly enriched in cancer-associated pathways in a way that the nicotine-exposed cells were not. The researchers noted that 6-MN appeared to have a greater effect on proteins linked to tumor development and spread.9PubMed. Comparative analyses of transcriptome sequencing and carcinogenic exposure toxicity of nicotine and 6-methyl nicotine in human bronchial epithelial cells
These are in vitro findings, meaning they come from cells in a dish rather than from people using 6-MN products for months or years. That’s an important caveat. But when cell studies consistently show a substance is more harmful than a comparator that we already know is dangerous, it’s a strong early warning signal.
A study using a three-dimensional human respiratory model, which more closely mimics actual lung tissue, confirmed that 6-MN aerosols have a different toxicological profile than nicotine aerosols, though it also found that the added flavorings in e-liquids could contribute similar levels of cell damage regardless of whether the base was 6-MN or nicotine. The study still concluded that 6-MN is not a safer alternative.10PubMed Central. A comparative toxicological evaluation of nicotine and its analog 6-methyl nicotine in E-cigarette aerosol utilizing a 3D in vitro human respiratory model
How Your Body Processes It Differently
One of the more interesting and underappreciated aspects of 6-MN is that your body breaks it down through a different biochemical route than nicotine. When you consume nicotine, your liver metabolizes it primarily through a pathway called C-oxidation, which is handled largely by the enzyme CYP2A6. That pathway produces cotinine, the metabolite doctors test for when they want to know if someone has been using tobacco.
6-MN gets metabolized too, and its breakdown products look structurally similar to nicotine’s metabolites, just heavier by 14 atomic mass units because of that extra methyl group. But the dominant route is different. Instead of going through the CYP2A6-dependent C-oxidation pathway, 6-MN is metabolized primarily through N-oxidation, likely driven by the enzyme FMO3. Researchers identified nine 6-MN metabolites in mouse urine, each corresponding to a known nicotine metabolite. Six of those metabolites were also found in the urine of people who had used Spree Bar products.11Toxicological Sciences. Characterizing oxidative metabolites of 6-methylnicotine (6MN; aka Metatine): divergent metabolism from nicotine and identification of urinary biomarkers of exposure
This metabolic divergence matters for two reasons. First, it means standard nicotine drug tests, which look for cotinine, may not detect 6-MN use. Second, the shift to a different enzymatic pathway raises questions about how the substance interacts with medications or genetic variations that affect those enzymes. People who are fast or slow metabolizers of nicotine because of CYP2A6 variants might respond very differently to 6-MN, but nobody has studied that yet.
The identification of specific urinary biomarkers for 6-MN exposure, including 6-methylcotinine and 6-methyl-3′-hydroxycotinine, gives researchers and public health officials a way to detect and track 6-MN use going forward.12PubMed Central. Characterizing oxidative metabolites of 6-methylnicotine (6MN; aka Metatine): divergent metabolism from nicotine and identification of urinary biomarkers of exposure That’s important because you can’t study the health effects of a substance in a population if you can’t measure who is actually exposed to it.
What’s Actually in These Products
If the toxicology is concerning, the quality control of 6-MN products is alarming. An analysis of commercially available e-cigarette products found staggering discrepancies between what was on the label and what was in the device. Spree Bar products, which declared 5% 6-methyl nicotine content, actually contained only about 0.6% 6-MN. That’s roughly one-eighth of the stated amount. Meanwhile, products from another brand called “Nixotine,” which was marketed as a nicotinamide product, contained 7 to 46% less of the declared nicotinamide content, and small amounts of 6-MN were also detected even though it wasn’t listed as an ingredient.13PubMed Central. Variability in Constituents of E-Cigarette Products Containing Nicotine Analogues
The same analysis found that all Spree Bar samples contained neotame, an artificial sweetener, at levels that weren’t declared on the packaging. These products aren’t just mislabeled in terms of their active ingredient; they contain undisclosed additives that consumers are inhaling without knowledge or consent.
For the average person picking up one of these devices at a vape shop, the situation is essentially a gamble. You don’t know how much 6-MN you’re getting, you don’t know what else is in there, and the substance itself has no established safe dose for human inhalation. Even if 6-MN turned out to be tolerable at some dose, users have no reliable way to control or even know what dose they’re receiving.
The Regulatory Gap That Made This Possible
The reason 6-MN products reached consumers in the first place is a regulatory loophole. In 2022, Congress amended the Tobacco Control Act to give the FDA authority over synthetic nicotine, not just tobacco-derived nicotine. But the question of whether 6-MN counts as “nicotine” or is something different has been slow to resolve. Because 6-MN isn’t nicotine itself but rather a nicotine analog with a slightly different molecular structure, some manufacturers have argued their products fall outside the FDA’s jurisdiction entirely.
Spree Bar products were marketed as “PMTA exempt,” referring to the Premarket Tobacco Product Application that manufacturers normally need to submit before selling new tobacco products.2PubMed Central. An electronic cigarette pod system delivering 6-methyl nicotine, a synthetic nicotine analog, marketed in the United States as “PMTA exempt” The researchers who first identified 6-MN in these products pointed out that the FDA needed to determine whether 6-methyl nicotine fell under the Tobacco Control Act as a form of nicotine, or whether it could alternatively be regulated as a drug under the broader Federal Food, Drug, and Cosmetic Act.
Oral pouch products containing nicotine analogs have taken a similar approach. Some brands include disclaimers stating that the product “is not considered a tobacco product” and “is not intended to diagnose, treat, cure, or prevent any disease,” language designed to stay on the legal boundary between a tobacco product and a drug without clearly being either. One brand, Hippotine, was specifically advertised as being available to Californians and “not subject to flavored pouch restriction,” directly positioning itself as a workaround for California’s ban on flavored tobacco products.14Tobacco Prevention & Cessation. Introduction of nicotine analogue-containing oral pouch products in the United States California responded by passing legislation in late September 2024 that explicitly classified 6-MN as a form of nicotine under state tobacco law, making such products subject to existing restrictions.
What Remains Unknown
The research on 6-MN so far is enough to say it’s not safe, but it’s far from complete. Virtually all of the toxicology comes from animal models and cell cultures. There are no published human clinical trials examining what happens to people who use 6-MN products regularly over weeks or months. Nobody has studied its cardiovascular effects in humans. Nobody has looked at what it does to developing brains in adolescents, the demographic most likely to pick up a flavored vape device.
A scoping review of the available literature on 6-MN and another nicotine analog, nicotinamide, concluded that the safety profiles of these analogs are “entirely unknown” and that the companies’ claims of being safer alternatives to nicotine lack any supporting evidence.15SpringerLink / Archives of Toxicology. A comparative toxicological evaluation of emerging nicotine analogs 6-methyl nicotine and nicotinamide: a scoping review The review’s authors speculated about potential mechanisms of toxicity involving oxidative stress and activation of certain ion channels and inflammatory pathways, but emphasized that actual data was scarce.
There’s also no understanding of how 6-MN interacts with other substances. Nicotine itself has well-documented interactions with caffeine metabolism, certain psychiatric medications, and hormonal contraceptives. Whether 6-MN follows the same interaction profile or introduces new ones is completely uncharted territory. The shift from CYP2A6-dominant metabolism to FMO3-dominant metabolism suggests the interaction landscape could differ meaningfully, but that’s speculation at this point, not data.
How to Tell if a Product Contains 6-MN
Given the labeling problems documented in these products, consumers can’t fully trust what’s printed on the box. That said, certain signals indicate a product contains or may contain 6-MN. The trade name “Metatine” is the most obvious indicator, and the brand most strongly associated with 6-MN has been Spree Bar. Newer oral pouch products may use other branding. Any product advertising itself as a “nicotine-free” alternative that still promises a nicotine-like experience should raise a red flag, because the whole point of 6-MN from a marketing perspective is to deliver the effects of nicotine while technically being something else.
If you’re a current user of one of these products and are concerned, the biomarker research described above means that a specialized lab test looking for 6-methylcotinine in urine could confirm exposure. Standard nicotine panels won’t detect it. This is also worth knowing for clinicians who see patients reporting unusual symptoms and using unfamiliar vape brands. Traditional cotinine testing won’t pick up what these patients are inhaling.
The natural trace amounts of 6-MN found in regular tobacco products are extremely low, far below the concentrations in synthetic 6-MN e-liquids. A conventional cigarette smoker would have negligible 6-MN exposure compared to someone using a Spree Bar. Analyses of past e-cigarette liquids that contained nicotine (not marketed as 6-MN products) found trace 6-MN levels averaging about 6 micrograms per milliliter, likely as a minor synthesis byproduct or natural contaminant, well below what dedicated 6-MN products are designed to deliver.1Scientific Reports. Levels of the nicotine analog 6-methyl nicotine as a naturally formed tobacco alkaloid in tobacco and tobacco products
Nicotine Analogs as a Category
6-MN is not the only nicotine analog being sold to consumers. Nicotinamide (also known as niacinamide, a form of vitamin B3) has appeared in some of the same product lines, with similar marketing claims about being a safer, unregulated alternative. The broader concern is that as regulators close loopholes around one analog, manufacturers can pivot to another. The original structure-activity research from the late 1990s examined an entire series of pyridine-substituted nicotine analogs. Some had reduced potency, others increased it. There is a library of possible analogs that could, in theory, be synthesized and marketed under the same regulatory evasion strategy.
This creates a cat-and-mouse dynamic familiar from other areas of consumer chemistry. Synthetic cannabinoids followed a similar trajectory: when one compound was banned, slightly different analogs appeared on shelves within months. California’s approach of defining 6-MN explicitly as a form of nicotine under state law may be more durable than compound-specific bans, because it addresses the functional category rather than the specific molecule. Whether federal regulation will follow a similar path remains to be seen. The FDA’s determination of how 6-MN fits into existing legal frameworks will likely set the precedent for how other nicotine analogs are treated going forward.